malignancy


Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

malignancy:

see cancercancer,
in medicine, common term for neoplasms, or tumors, that are malignant. Like benign tumors, malignant tumors do not respond to body mechanisms that limit cell growth.
..... Click the link for more information.
.
References in periodicals archive ?
There's a lot of things going on in the media about morcellation and risk of malignancy at the time of benign fibroid surgery, but this research actually makes apparent the higher risk of malignancy when fibroids are not present," Farah Alvi, MD, a second-year fellow at Northwestern University, Chicago, said in an interview.
All cases that meet diagnostic criteria that are not associated with malignancy or drug exposure are categorized as classical Sweet's syndrome.
The diagnosis and type of malignancy were confirmed via histopathological examination of a biopsy specimen.
Carcinoma of the thyroid gland is the most common endocrine malignancy in the world, and worldwide it constitutes about 1% of human neoplasms.
Subjects and Methods: Fifty cases of solitary/multinodular goitre with clinical suspicion of malignancy were included in the study by non-probability purposive sampling.
Causes of microscopic hematuria are variable and include urinary stones, infection and genitourinary malignancy.
Chi-square test was used to find out the association of type of malignancy and vitamin B12 and folate deficiency and also to compare the deficiency between cases and controls.
Basal cell carcinoma (BCC) was the most common malignancy consisting of 32(32%) cases followed by Squamous cell carcinoma (SCC 18%) with 10 (10%) cases of melanoma and 9(9%) cases of Mycosis Fungoides.
ClickPress, Mon Oct 07 2013] Global Markets Direct's, 'Nonhematologic Malignancy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline.
M2 EQUITYBITES-August 30, 2013-Pharmacyclics Inc granted US FDA's priority review for NDA for ibrutinib for two B-cell malignancy indications(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-August 30, 2013-Pharmacyclics Inc granted US FDA's priority review for NDA for ibrutinib for two B-cell malignancy indications(C)2013 M2 COMMUNICATIONS